Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy

RegulatoryapprovedHBM7575/SKB575Positive

AI Analysis

Summary

Harbour BioMed and Kelun-Biotech received IND approval from China's NMPA for HBM7575/SKB575, a bispecific antibody designed to treat asthma. This regulatory milestone permits the initiation of clinical trials in China for the candidate therapy.

Outcome Details

IND approval from China's NMPA

Importance:6/10

Sentiment:

0.70

ChinaIND approvalNMPAbispecific antibodyasthma

Related Companies

$CHHE

Read the original article

Published by Pharmaceutical Technology on July 16, 2026 8:59 AM

Read Original